A Study of ABT-751 in Patients With Renal Cell Cancer
- Conditions
- Renal Cell Cancer
- Registration Number
- NCT00073112
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Objective Response Rate in subjects with RCC 1 year
- Secondary Outcome Measures
Name Time Method Time to Tumor Progression (TTP) 1 year Survival 2 years Toxicities associated with treatment administration 1 year
Trial Locations
- Locations (23)
Arizona Cancer Research Center
🇺🇸Tucson, Arizona, United States
UCLA School of Medicine
🇺🇸Los Angeles, California, United States
Clinical Trials + Research Associates
🇺🇸Montebello, California, United States
US Oncology Inc Rocky Mountain Cancer Centers
🇺🇸Denver, Colorado, United States
Oncology Hematology Group of South Florida
🇺🇸Miami, Florida, United States
US Oncology Inc Florida Cancer Institute
🇺🇸New Port Richey, Florida, United States
US Oncology Inc Ocala Oncology Center
🇺🇸Ocala, Florida, United States
US Oncology Inc Cancer Centers of Florida, P.A.
🇺🇸Orlando, Florida, United States
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Sidney Kimmel Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Scroll for more (13 remaining)Arizona Cancer Research Center🇺🇸Tucson, Arizona, United States